HBMH.F Stock Overview A clinical-stage biopharmaceutical company, engages in the discovery and development of differentiated antibody therapeutics in immunology and oncology disease areas. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
HBM Holdings Limited Competitors Price History & Performance
Summary of share price highs, lows and changes for HBM Holdings Historical stock prices Current Share Price HK$0.48 52 Week High HK$0.48 52 Week Low HK$0.48 Beta 0 1 Month Change 0% 3 Month Change n/a 1 Year Change n/a 3 Year Change n/a 5 Year Change n/a Change since IPO 1.07%
Recent News & Updates
Harbour BioMed Appoints Dr. Raymond Zheng as Chief Business Officer Nov 15
HBM Holdings Limited Announces Submission of Investigational New Drug Application for HBM9378\SKB378 (ANTI-TSLP) for COPD to the National Medical Products Administration of China Nov 08
HBM Holdings Limited Appoints Yifan Gao as Joint Company Secretary Oct 24
Harbour BioMed Announces Publication of the Phase I Study Results for Porustobart in Combination with Toripalimab in Advanced Melanoma and Other Solid Tumors Oct 10
Harbour Biomed Announces the Latest Clinical Data on the First-In-Class Fully Human Anti-B7h7/Hhla2 Monoclonal Antibody Hbm1020 At the Esmo Congress 2024 Sep 14
HBM Holdings Limited to Report First Half, 2024 Results on Aug 28, 2024 Aug 05 See more updates
Harbour BioMed Appoints Dr. Raymond Zheng as Chief Business Officer Nov 15
HBM Holdings Limited Announces Submission of Investigational New Drug Application for HBM9378\SKB378 (ANTI-TSLP) for COPD to the National Medical Products Administration of China Nov 08
HBM Holdings Limited Appoints Yifan Gao as Joint Company Secretary Oct 24
Harbour BioMed Announces Publication of the Phase I Study Results for Porustobart in Combination with Toripalimab in Advanced Melanoma and Other Solid Tumors Oct 10
Harbour Biomed Announces the Latest Clinical Data on the First-In-Class Fully Human Anti-B7h7/Hhla2 Monoclonal Antibody Hbm1020 At the Esmo Congress 2024 Sep 14
HBM Holdings Limited to Report First Half, 2024 Results on Aug 28, 2024 Aug 05
Harbour BioMed to Present the Latest Progress of the First-In-Class Fully Human Anti-B7H7/HHLA2 Monoclonal Antibody HBM1020 at the ESMO Congress 2024 Jul 26
HBM Holdings Limited Provides Earnings Guidance for the Six Months Ended June 30, 2023 Jul 19
Harbour BioMed Announces Resubmission of Biologics License Application for Batoclimab to NMPA for Treatment of Generalized Myasthenia Gravis Jun 27
HBM Holdings Limited, Annual General Meeting, Jun 06, 2024 Mar 29
HBM Holdings Limited to Report Fiscal Year 2023 Results on Mar 28, 2024 Mar 14
Harbour BioMed Announces IND Clearance for HBM9027 in the U.S Jan 24
HBM Holdings Limited Provides Earnings Guidance for the Year Ended 31 December 2023 Jan 19
HBM Holdings Limited Announces Executive Changes Oct 20
Harbour BioMed Announces US IND Clearance of Its First ADC Program HBM9033 in Solid Tumors Aug 29
HBM Holdings Limited to Report First Half, 2023 Results on Aug 28, 2023 Aug 18
Harbour BioMed Appoints Dr. Albert R. Collinson as Independent Non-Executive Director Aug 09 HBM Holdings Limited Announces Board Changes
National Medical Products Administration of China Accepts Biologics License Application for HBM Holdings Limited's Batoclimab for Treatment of gMG Jun 30
HBM Holdings Limited Appoints Steve Arkinstall as Chief Scientific Advisor of Nona Biosciences Jun 07
Harbour BioMed Announces First Patient Dosed in Phase I Study of First-In-Class Anti-B7H7 (HHLA2) Antibody HBM1020 Jun 05
Harbour BioMed Reports Results of Phase Ib Clinical Trial of Porustobart in Combination of Toripalimab in Patients with Hepatocellular Carcinoma at ASCO 2023 May 29
Hbm Holdings Limited Announces Food and Drug Administration of the United States Investigational New Drug Clearance for HBM1020 Clinical Trial Initiation Jan 13
Hbm Holdings Limited Announces Results from Phase I Clinical Trial of Porustobart (Hbm4003)In Combination with Toripalimab in Advanced Melanoma Dec 09
WuXi Vaccines (Hong Kong) Limited entered into an agreement to acquire Manufacturing facility in Suzhou from HBM Holdings Limited (SEHK:2142). Nov 16 HBM Holdings Limited Appoints Mr. Weihao Xu as Chief Business Officer
Harbour BioMed Announces Dosing of First Patient in Phase I Trial of B7H4x4-1BB Bispecific Antibody in the United States Oct 21
Hbm Holdings Limited Announces Closing the Study of Phase III Clinical Trial of Tanfanercept (Hbm9036) Oct 11 Harbour BioMed Announces First Subject Dosed in Phase I Study of Next-Gen Anti-TSLP Fully Human Monoclonal Antibody
Hbm Holdings Limited Announces Completion of First Dosing of Last Patient with Hbm4003 Phase Ib Trial Aug 16
Harbour BioMed Announces the Preclinical Results of Porustobart Aug 09
HBM Holdings Limited to Report First Half, 2022 Results on Aug 31, 2022 Aug 03
Harbour BioMed Announces IND Clearance for B7H4x4-1BB Bispecific Antibody by the U.S. Food and Drug Administration Jun 28
HBM Holdings Limited Announces IND Approval for Commencement of Phase I Trial of B7H4X4-1BB Bispecific Antibody in China Jun 09
Hbm Holdings Limited Announces Data Release of Next-Gen Ctla-4 Antibody At Asco 2022 Jun 02
HBM Holdings Limited Announces That Dosing of First Patient in Phase I Trial of B7h4x4-1Bb Bispecific Antibody Hbm7008 Has Been Completed May 26
Hbm Holdings Limited Announces Data Release Forecast of Hbm4003 At ASCO 2022 May 12
HBM Holdings Limited Announces Board Changes May 08
Harbour BioMed Appoints Dr. Alexander A. Zukiwski to its Scientific Advisory Board May 06
Harbour BioMed Appoints Humphrey Gardner as Chief Medical Officer Apr 14 Shareholder Returns HBMH.F US Biotechs US Market 7D 0% -5.6% -3.5% 1Y n/a -1.5% 22.1%
See full shareholder returns
Return vs Industry: Insufficient data to determine how HBMH.F performed against the US Biotechs industry .
Return vs Market: Insufficient data to determine how HBMH.F performed against the US Market .
Price Volatility Is HBMH.F's price volatile compared to industry and market? HBMH.F volatility HBMH.F Average Weekly Movement n/a Biotechs Industry Average Movement 10.7% Market Average Movement 6.3% 10% most volatile stocks in US Market 17.0% 10% least volatile stocks in US Market 3.1%
Stable Share Price: HBMH.F has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine HBMH.F's volatility change over the past year.
About the Company HBM Holdings Limited, a clinical-stage biopharmaceutical company, engages in the discovery and development of differentiated antibody therapeutics in immunology and oncology disease areas. It is developing Batoclimab (HBM9161), a human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor; Tanfanercept (HBM9036) to treat moderate to-severe dry eye disease; HBM7008, a bispecific antibody targeting tumor Associated antigen; and HBM4003, a human anti-CTLA-4 antibody against cytotoxic T-lymphocyte-associated antigen-4. The company is also developing HBM9022 for the treatment of SARS-COV-2; HBM9302 for the treatment of breast and gastric cancers; HBM7020 for the treatment of multiple myeloma; and HBM1007, HBM1029, HBM7015, HBM7008, and HBM1022 for the treatment of solid tumors.
Show more HBM Holdings Limited Fundamentals Summary How do HBM Holdings's earnings and revenue compare to its market cap? HBMH.F fundamental statistics Market cap US$362.31m Earnings (TTM ) -US$137.78m Revenue (TTM ) US$4.31m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) HBMH.F income statement (TTM ) Revenue US$4.31m Cost of Revenue US$137.00k Gross Profit US$4.17m Other Expenses US$141.95m Earnings -US$137.78m
Last Reported Earnings
Dec 31, 2021
Earnings per share (EPS) -0.19 Gross Margin 96.82% Net Profit Margin -3,198.17% Debt/Equity Ratio 5.4%
How did HBMH.F perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2022/07/11 05:29 End of Day Share Price 2022/04/13 00:00 Earnings 2021/12/31 Annual Earnings 2021/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources HBM Holdings Limited is covered by 7 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Bo Li BofA Global Research Tony Ren CLSA null null Credit Suisse
Show 4 more analysts 